A Dalhoff
Overview
Explore the profile of A Dalhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
1053
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagenlehner F, Nowicki M, Bentley C, Luckermann M, Wohlert S, Fischer C, et al.
Antimicrob Agents Chemother
. 2018 Jan;
62(4).
PMID: 29339395
The broad-spectrum C-8-cyano-fluoroquinolone finafloxacin displays enhanced activity under acidic conditions. This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract...
2.
Dalhoff A, Schubert S, Vente A
Antimicrob Agents Chemother
. 2017 Feb;
61(5).
PMID: 28193648
The pharmacodynamics of finafloxacin, ciprofloxacin, and levofloxacin against extended-spectrum-β-lactamase (ESBL)-producing isolates were compared. Since quinolones lose activity in acidic media, and particularly in urine, their activities were tested in parallel...
3.
Dalhoff A, Rashid M, Kapsner T, Panagiotidis G, Weintraub A, Nord C
Clin Microbiol Infect
. 2015 Jun;
21(8):767.e1-4.
PMID: 26047854
The water-soluble prodrug MCB3837 is rapidly converted to MCB3681, active against Gram-positive bacterial species, after intravenous infusion. The aim of this study was to prove the principle that MCB3681 is...
4.
Dalhoff A
Eur J Clin Microbiol Infect Dis
. 2014 Dec;
34(4):661-8.
PMID: 25515946
This review summarizes evidence that commercially available fluoroquinolones used for the treatment of bacterial infections are active against other non-bacterial infectious agents as well. Any of these fluoroquinolones exerts, in...
5.
Dalhoff A
Infection
. 2012 Mar;
40(3):239-62.
PMID: 22460782
Introduction: This review summarizes data on the fluoroquinolone resistance epidemiology published in the previous 5 years. Materials And Methods: The data reviewed are stratified according to the different prescription patterns...
6.
Dalhoff A, Ambrose P, Mouton J
Infection
. 2009 Jul;
37(4):296-305.
PMID: 19629383
Since the origin of an "'International Collaborative Study on Antibiotic Sensitivity Testing'" in 1971, considerable advancement has been made to standardize clinical susceptibility testing procedures of antimicrobial agents. However, a...
7.
Dalhoff A
Infection
. 2006 Mar;
33 Suppl 2:55-70.
PMID: 16518713
A review of published data on the in vitro, ex vivo, in vivo and clinical effects of fluoroquinolones on the synthesis of cytokines is provided. Fluoroquinolones (FQs) were found to...
8.
Dalhoff A
Infection
. 2006 Mar;
33 Suppl 2:44-9.
PMID: 16518711
Traditional in vitro models used to simulate human pharmacokinetics and to characterize the pharmacodynamics of antibacterial agents represent a totally immunosuppressed condition. However, host defense mechanisms contribute to the elimination...
9.
Dalhoff A, Schubert S, Ullmann U
Infection
. 2006 Mar;
33 Suppl 2:36-43.
PMID: 16518710
Antibiotic activity against common respiratory pathogens can be affected by the pH of the medium (in vitro) or the bodily fluid (in vivo) in which bacteria are present. The ionized...
10.
Stass H, Dalhoff A
Infection
. 2006 Mar;
33 Suppl 2:29-35.
PMID: 16518709
For fluoroquinolones AUC/MIC ratios are known to correlate with clinical outcomes for patients suffering from respiratory tract infections (RTI) and complicated skin and skin structure infections (cSSSI). This paper describes...